These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 29395502)

  • 1. Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial.
    Ahlgren GM; Flodgren P; Tammela TLJ; Kellokumpu-Lehtinen P; Borre M; Angelsen A; Iversen JR; Sverrisdottir A; Jonsson E; Sengelov L;
    Eur Urol; 2018 Jun; 73(6):870-876. PubMed ID: 29395502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial.
    Kellokumpu-Lehtinen PL; Hjälm-Eriksson M; Thellenberg-Karlsson C; Åström L; Franzen L; Fransson AS; Leskinen MJ; Zeke M; Huttunen T; Ginman C;
    Eur Urol; 2019 Dec; 76(6):823-830. PubMed ID: 31443961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series.
    Fossati N; Karnes RJ; Boorjian SA; Moschini M; Morlacco A; Bossi A; Seisen T; Cozzarini C; Fiorino C; Noris Chiorda B; Gandaglia G; Dell'Oglio P; Joniau S; Tosco L; Shariat S; Goldner G; Hinkelbein W; Bartkowiak D; Haustermans K; Tombal B; Montorsi F; Van Poppel H; Wiegel T; Briganti A
    Eur Urol; 2017 Jun; 71(6):886-893. PubMed ID: 27484843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
    Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study.
    Kibel AS; Rosenbaum E; Kattan MW; Picus J; Dreicer R; Klein EA; Chatta GS; Nelson JB; DiPaola RS; Roth BJ; Cookson MS; Wilding G; Jarrard DF; Beer TM; Ryan CW; Petrylak DP; Benson MC; Partin AW; Garrett-Mayer E; Eisenberger MA
    J Urol; 2007 May; 177(5):1777-81. PubMed ID: 17437819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial.
    Wiegel T; Bartkowiak D; Bottke D; Bronner C; Steiner U; Siegmann A; Golz R; Störkel S; Willich N; Semjonow A; Stöckle M; Rübe C; Rebmann U; Kälble T; Feldmann HJ; Wirth M; Hofmann R; Engenhart-Cabillic R; Hinke A; Hinkelbein W; Miller K
    Eur Urol; 2014 Aug; 66(2):243-50. PubMed ID: 24680359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension.
    Hackman G; Taari K; Tammela TL; Matikainen M; Kouri M; Joensuu T; Luukkaala T; Salonen A; Isotalo T; Pétas A; Hendolin N; Boström PJ; Aaltomaa S; Lehtoranta K; Hellström P; Riikonen J; Korpela M; Minn H; Kellokumpu-Lehtinen PL; Pukkala E; Hemminki A;
    Eur Urol; 2019 Nov; 76(5):586-595. PubMed ID: 31375279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621.
    Hurwitz MD; Harris J; Sartor O; Xiao Y; Shayegan B; Sperduto PW; Badiozamani KR; Lawton CAF; Horwitz EM; Michalski JM; Roof K; Beyer DC; Zhang Q; Sandler HM
    Cancer; 2017 Jul; 123(13):2489-2496. PubMed ID: 28323339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Veterans Affairs Cooperative Studies Program Study #553: Chemotherapy After Prostatectomy for High-risk Prostate Carcinoma: A Phase III Randomized Study.
    Lin DW; Shih MC; Aronson W; Basler J; Beer TM; Brophy M; Cooperberg M; Garzotto M; Kelly WK; Lee K; McGuire V; Wang Y; Lu Y; Markle V; Nseyo U; Ringer R; Savage SJ; Sinnott P; Uchio E; Yang CC; Montgomery RB
    Eur Urol; 2020 May; 77(5):563-572. PubMed ID: 31924316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 3 study of adjuvant radiotherapy versus wait and see in pT3 prostate cancer: impact of pathology review on analysis.
    Bottke D; Golz R; Störkel S; Hinke A; Siegmann A; Hertle L; Miller K; Hinkelbein W; Wiegel T
    Eur Urol; 2013 Aug; 64(2):193-8. PubMed ID: 23522911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Positive Surgical Margins after Radical Prostatectomy on Disease Progression and Adjuvant Treatment in Pathologically Localized Prostate Cancer.
    Tomasković I; Milicić V; Tomić M; Ruzić B; Ulamec M
    Coll Antropol; 2015 Sep; 39(3):697-700. PubMed ID: 26898068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis.
    Briganti A; Karnes RJ; Da Pozzo LF; Cozzarini C; Capitanio U; Gallina A; Suardi N; Bianchi M; Tutolo M; Salonia A; Di Muzio N; Rigatti P; Montorsi F; Blute M
    Eur Urol; 2011 May; 59(5):832-40. PubMed ID: 21354694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.
    Hamdy FC; Donovan JL; Lane JA; Mason M; Metcalfe C; Holding P; Wade J; Noble S; Garfield K; Young G; Davis M; Peters TJ; Turner EL; Martin RM; Oxley J; Robinson M; Staffurth J; Walsh E; Blazeby J; Bryant R; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Powell P; Prescott S; Rosario D; Rowe E; Neal D
    Health Technol Assess; 2020 Aug; 24(37):1-176. PubMed ID: 32773013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
    Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
    Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
    Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
    Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.
    Touijer KA; Karnes RJ; Passoni N; Sjoberg DD; Assel M; Fossati N; Gandaglia G; Eastham JA; Scardino PT; Vickers A; Cozzarini C; Montorsi F; Briganti A
    Eur Urol; 2018 Jun; 73(6):890-896. PubMed ID: 29042125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Prior Local Treatment on the Outcomes of Metastatic Hormone-Sensitive Prostate Cancer: Secondary Analysis of a Randomized Controlled Trial.
    Abdel-Rahman O; Cheung WY
    Clin Genitourin Cancer; 2018 Dec; 16(6):466-472. PubMed ID: 30098982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis.
    Gandaglia G; Boorjian SA; Parker WP; Zaffuto E; Fossati N; Bandini M; Dell'Oglio P; Suardi N; Montorsi F; Karnes RJ; Briganti A
    Eur Urol; 2017 Dec; 72(6):910-917. PubMed ID: 28622831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.